http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 28 Oct 2026 05:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html <p>VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, and Boston-based Celvion Therapeutics (“Celvion”), today announced the completion of the first analysis in their collaboration using Celvion’s EMphora™ artificial intelligence platform to evaluate potential treatment strategies for Rakovina’s ATR inhibitor program.</p> <p>The analysis identified two priority cancer indications for a second, in-depth analysis. The findings provide a focused framework for determining which treatment strategies warrant further investigation as Rakovina advances development of its ATR inhibitor http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html Wed, 28 Oct 2026 05:30:00 -0400 RKV RKVTF http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html <p>VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, and Boston-based Celvion Therapeutics (“Celvion”), today announced the completion of the first analysis in their collaboration using Celvion’s EMphora™ artificial intelligence platform to evaluate potential treatment strategies for Rakovina’s ATR inhibitor program.</p> <p>The analysis identified two priority cancer indications for a second, in-depth analysis. The findings provide a focused framework for determining which treatment strategies warrant further investigation as Rakovina advances development of its ATR inhibitor http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html Wed, 28 Oct 2026 05:30:00 -0400 RKV RKVTF http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html <p>VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, and Boston-based Celvion Therapeutics (“Celvion”), today announced the completion of the first analysis in their collaboration using Celvion’s EMphora™ artificial intelligence platform to evaluate potential treatment strategies for Rakovina’s ATR inhibitor program.</p> <p>The analysis identified two priority cancer indications for a second, in-depth analysis. The findings provide a focused framework for determining which treatment strategies warrant further investigation as Rakovina advances development of its ATR inhibitor http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html Wed, 28 Oct 2026 05:30:00 -0400 RKV RKVTF http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html <p>VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, and Boston-based Celvion Therapeutics (“Celvion”), today announced the completion of the first analysis in their collaboration using Celvion’s EMphora™ artificial intelligence platform to evaluate potential treatment strategies for Rakovina’s ATR inhibitor program.</p> <p>The analysis identified two priority cancer indications for a second, in-depth analysis. The findings provide a focused framework for determining which treatment strategies warrant further investigation as Rakovina advances development of its ATR inhibitor http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+and+Celvion+Therapeutics+Complete+AI+Analysis+Identifying+Priority+Cancer+Indications+for+Brain-Penetrant+ATR+Inhibitor+Program/27243622.html Wed, 28 Oct 2026 05:30:00 -0400 RKV RKVTF